A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs

Eur J Clin Microbiol Infect Dis. 1998 Jun;17(6):420-3. doi: 10.1007/BF01691575.

Abstract

The in vivo efficacy of trovafloxacin, intraperitoneally administered as alatrofloxacin (CP-116,517), was assessed and compared with that of erythromycin, alone or in combination with rifampicin, in a model of Legionella pneumophila pneumonia in guinea pigs. Trovafloxacin (5 mg/kg administered as alatrofloxacin once daily for 7 days) gave a survival rate of 100% in infected animals. Clearance of bacteria and of bacteria-induced lesions from lungs was achieved by day 6 post-inoculation. The lungs of trovafloxacin-treated animals remained free of bacteria at day 28 post-challenge. Trovafloxacin proved as effective as erythromycin administered intraperitoneally, but was superior to erythromycin alone. or in combination with rifampicin, when given orally.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Animals
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Drug Evaluation, Preclinical
  • Drug Therapy, Combination / administration & dosage
  • Drug Therapy, Combination / therapeutic use
  • Erythromycin / administration & dosage
  • Erythromycin / therapeutic use
  • Female
  • Fluoroquinolones*
  • Guinea Pigs
  • Injections, Intraperitoneal
  • Legionella pneumophila / drug effects
  • Legionnaires' Disease / drug therapy*
  • Legionnaires' Disease / microbiology
  • Lung / microbiology
  • Microbial Sensitivity Tests
  • Prodrugs / therapeutic use*
  • Random Allocation
  • Rifampin / administration & dosage
  • Rifampin / therapeutic use

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Prodrugs
  • Erythromycin
  • alatrofloxacin
  • Rifampin